If you cannot access ON24, please access this here.
The webinar’s learning objectives include:
- Understanding the role of Whole Pelvic Radiotherapy (WPRT) in Prostate Cancer Treatment, including its potential to enhance survival and its rationale in treating both node-negative and node-positive prostate cancer patients.
- Evaluating WPRT Optimization with Advanced Imaging Techniques, such as the role of PSMA PET CT in refining WPRT for node-positive prostate cancer and the influence of contemporary imaging on radiation treatment planning and outcomes.
- Analyzing Clinical Trial Outcomes on Pelvic Radiotherapy, including a review of pivotal trial results comparing pelvic irradiation to prostate-only irradiation and summarizing long-term survival data and clinical practice implications.
- Comparing Radiotherapy Techniques and Their Effectiveness, contrasting the efficacy and side effect profiles of different radiotherapy techniques in prostate cancer treatment and discussing the practicality and safety of SBRT in node-positive prostate cancer.
Presenter: Vedang Murthy, M.D., DNB, DipEPP, Tata Memorial Centre, Mumbai, India
Vedang Murthy is a Professor of Radiation Oncology at Tata Memorial Centre, Mumbai. Dr. Murthy also trained at The Royal Marsden NHS Foundation Hospital, London and undertook a Diploma in Epidemiology and Biostatistics from the London School of Hygiene and Tropical Medicine. Dr Murthy is the Convenor of the Uro Oncology Disease Management group at the Tata Memorial Hospital and is currently running investigator-initiated randomised prostate and bladder cancer trials.
Research focus: Stereotactic Body Radiation Therapy and Pelvic Radiation Therapy for high-risk prostate cancer, prostate-specific membrane antigen positron emission tomography (PSMA PET) in Prostate cancer, bladder preservation and adjuvant radiotherapy in bladder cancer and radiotherapy in seminoma and advanced penile cancers.
Moderator: Seth Blacksburg, M.D., MBA, Senior Vice President, Chief Medical Officer, Accuray
Seth Blacksburg is a board-certified radiation oncologist who earned a master of business administration degree while completing his medical studies concurrently. Dr. Blacksburg is highly skilled in all facets of radiation oncology, with expertise in stereotactic body radiotherapy (SBRT) and radiosurgery for prostate cancer, breast cancer, CNS cancers, and other tumor sites, LDR and HDR brachytherapy, and integrating radiation with immunotherapy.
He serves as SVP, CMO of Accuray. Prior to joining Accuray, Dr. Blacksburg was chairman of radiation medicine at Lenox Hill Hospital, a part of Northwell Health, the largest private employer in New York (state). Dr. Blacksburg was responsible for the department’s clinical oversight and strategic development. He also served as a key member of the hospital’s cancer committee, medical board and national accreditation programs for breast and rectal cancers. During Dr. Blacksburg’s tenure with the Lenox Hill cancer program, the cancer program achieved Commission on Cancer (CoC) accreditation and the department’s patient volume increased significantly.
Prior to joining Lenox Hill, Dr. Blacksburg served as associate director of radiation oncology and medical director of NYCyberKnife Center at NYU Winthrop Hospital. In addition, he held the academic title of clinical associate professor at the NYU Long Island School of Medicine. He was also previously a radiation oncologist at the Icahn School of Medicine at Mount Sinai Hospital. Throughout his career, Dr. Blacksburg has been the principal and senior researcher in a wide array of clinical investigations, which have primarily focused on stereotactic radiation therapy and treatment outcomes for genitourinary cancers. As a highly sought-after expert within his field, he has been invited to lecture, teach and present at numerous national and international conferences.
Dr. Blacksburg is affiliated with the American Society for Radiation Oncology and the American Board of Radiology. He also serves as a reviewer for several distinguished academic journals. After graduating summa cum laude from Tufts University, Dr. Blacksburg concurrently pursued a medical degree from the Duke University School of Medicine, where he served as class president, and a Master of Business Administration degree with a concentration in health sector management from the Duke University Fuqua School of Business.
His post-graduate training included an internship in internal medicine at New York University/Bellevue Hospital and a residency in radiation oncology at the Icahn School of Medicine at Mount Sinai, where he served as chief resident for two years. He stayed on as faculty at Mount Sinai, where he was the first radiation oncologist selected for the Greater New York Hospital Association/United Hospital Fund clinical quality fellowship.
